As I mentioned this morning in the daily update, there are two positions that expire today.
The first position is HOG and as I write this it is trading around $23.10 or slightly above the strike price. Leave this position alone for now and lets wait to see where it
settles at the close today.
The second position is the short $18 call on OSTK.
My suggestion is to buy back the May 22nd call for $.20.
After you close the position that expires today, then Sell to Open (1) May 29th - $18 call for every 100 shares you own.
The May 29th - $18 call can be sold for $1.25.
You pick up a gain of 35 cents per share on the call that expires today and another $1.25 per share for the calls that expire next Friday.
Of course, this alert only applies to you if you bought shares in OSTK.
As a reminder, all markets are closed this Monday for the Memorial Day Holiday here in the States.
Enjoy your holiday weekend!
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png00Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-05-22 11:42:402020-05-22 11:42:40May 22, 2020 - MDT Alert (OSTK)
What does it mean for companies to apply data to gain an edge?
Let me explain.
Data is best described as the oxygen that is provided to the lungs.
Competition is based on the business intelligence excavated from vast troves of data.
These insights enable companies to target proper growth drivers, migrate to revenue hotspots and add appropriate employee talent.
The data also delves into how to create product stickiness, customer loyalty, promote up-selling, and optimize operations.
It’s not me just saying this to hype up the phenomenon, and I can vouch that data-driven decisions have worked wonders for the Mad Hedge Technology Letter.
Other companies have reported robust performance in productivity and profitability margins up to 10% higher than analog companies.
A recent report showed that margins would expand wider after the first year to 10% and hit a roaring 15% after operations are further refined.
It's a world of data supremacy; it doubles in size every two years and will reach 70 zettabytes by next year.
Data is connected to every part of the model from marketing campaigns, to website traffic flow and activity engagement, to operational procedures.
Can you believe that only 10% of global data is currently being acted on?
It’s hard to digest that most companies are winging it without any rhyme or reason.
The world is way too complex to bring a knife to a gunfight.
Predictive insights used to be only reserved for Fortune 500 companies who could afford the high expense of applying these high-powered tools.
But after the recent wave of automation and cloud software, even individual proprietors can participate in this once-taboo management exercise because the costs have come down.
Going on gut instinct and best estimates can only get you so far in a rapidly digitizing world and the coronavirus has only made the volume of data explode and required insights into business that are much more important.
I would also say that companies must be vigilant in harnessing the data because the skyrocketing number of nefarious elements out there have corrupted many data forms.
Just recently, the Mad Hedge website was overpowered by a tsunami of bots scouring our website for data.
The bots overloaded our email distributer service with new subscriptions by registering 1000s of emails into our database which muddied our underlying data and our ability to glean salient insights into it.
Bots find the data needed to answer a question or solve a problem and the Mad Hedge Fund Trader website has been a target to find the best financial content in the English-speaking world.
Once the requisite data is in hand, bots identify what toolsets are needed to organize the data and produce predictive and prescriptive business insights.
Many of these bots use content to create trading algorithms based on stand-alone content from the Mad Hedge Fund Trader that acts as a direct input into the database.
This new form of business intelligence deploys machine learning software as a question or problem and generate actionable solutions.
They can categorize base cases, outliers, marginal cases, and errors that require further data cleaning, additional reporting, and queries.
Ultimately, these bots are the vehicles in which a final answer is populated such as whether or not to buy Amazon stock today or tomorrow and so on.
As we push into the 5G era, this same technology will be repurposed for the internet of things (IoT) translating into another wave of products being groomed and fine-tuned by machine learning.
Internet of Things (IoT) is the fastest-growing segment of data and already comprises 15% of total global data.
Physical products will need embedded sensors that will monitor the performance and send terabytes of data back to the data servers for data analysts to pick apart.
One example is a Geared Turbo Fan engine which requires 5,000 sensors that generate up to 10 GB of data per second.
Now you can understand why the volume of data is literally about to mushroom as 5G takes hold and why Amazon has been so hellbent in penetrating the smart home market.
Bots facilitate conversations between systems and data silos and allow your decision-makers to have the keys to the Ferrari.
Bots enable an easy view of displaying key performance indicators (KPIs) and alerts on the run with simple charts and graphs.
As the coronavirus offers us glimpses into the world tomorrow, data analysts embedded all over the world will be harnessing bots to maintain your home thermostat or upgrade software in the rear of your smart microwave.
As we speak, the Mad Hedge Fund Trader website is gearing up for the next wave of data supremacy and I advise everyone else to get with the program.
This is the world of the future and for companies who don’t adapt, they will be swept into the dustbin of history.
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png00Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-05-22 10:02:572020-06-22 11:41:39Why Data Has Become the Oxygen of Modern Commerce
“The sidelines are not where you want to live your life. The world needs you in the arena.” – Said CEO of Apple Tim Cook
https://www.madhedgefundtrader.com/wp-content/uploads/2020/05/tim-cook.png193169Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-05-22 10:00:562020-05-22 10:54:13May 22, 2020 - Quote of the Day
While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points.Read more
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png00Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-05-22 09:32:182020-05-22 13:40:12May 22, 2020 - MDT Pro Tips
Zoetis (ZTS) has been an investor darling since it was spun off from Pfizer way back in 2013. From day one, since this animal healthcare stock went public, shares have soared by 382%.
This stock’s popularity among growth investors stemmed from two emerging trends today. The first is the “humanization” of our pets through healthcare. The second is the rise in global demand for animal protein.
Both tailwinds have been responsible for the steady growth of Zoetis and are anticipated to continue to do so in the years to come.
With everything that has happened since we welcomed 2020, is Zoetis still a good stock to buy?
Earlier this month, Zoetis released its fourth-quarter earnings report for 2019. As usual, the company once again impressed its investors by beating estimates.
The company reported a quarterly revenue of $1.7 billion, indicating a 7% improvement from its performance in the same quarter in 2018.
Adjusted net income came in at $440 million, breaking down to earnings per share of $0.92.
In comparison, Wall Street estimates pegged Zoetis’ quarterly revenue at $1.6 billion with an EPS of $0.88.
Notably, Zoetis’ international business segments and its US market are practically equal in terms of size. Its US market raked in $861 million in revenue, showing off a 6% boost in this quarter. Meanwhile, its international sales increased by 9% to reach $791 million.
Although all these are enough to make investors happy, Zoetis’ 2020 guidance gave some of its investors pause.
According to the company, it estimates a jump in its annual growth somewhere between 5.5% and 8%, pushing its revenue from $6.3 billion to reach an amount somewhere between $6.65 billion and $6.8 billion.
However, this projection has been met with skepticism in light of COVID-19.
Looking at its reports, roughly 3% or $200 million of Zoetis’ sales last year came from China.
Despite this, Zoetis appears to be confident that it can hit its goals this year.
The company’s companion animal business, which primarily sells medicines for cats and dogs, picked up the slack from the decline of its beef and dairy cattle markets.
In fact, revenue from the companion animal arm showed an 18% jump year over year and reached $784 million.
One of the main drivers in this sector is Zoetis’ dermatology brands, Apoquel and Cytopoint. Both are estimated to bring in roughly $700 million in annual sales. Boosting this momentum are the company’s parasiticide items like ProHeart 12 and Simparica.
However, it’s the launch of Simparica Trio that generated excitement among Zoetis investors.
Simparica Trio is the company’s new chewable “triple combination parasiticide for dogs.” According to the company’s guidelines, this product is expected to add at least $150 million in revenue for the last three quarters of 2020.
This new drug’s appeal lies in the fact that it can simplify the lives of pet owners. Simparica Trio only needs to be administered once a month.
After that, the pill can be relied on as a preventive measure against heartworm disease. It can also control ticks, intestinal nematodes, and fleas in dogs. With Simparica Trio, pet owners no longer need to buy and administer multiple products.
To date, this medicine has received regulatory approval in Canada and the European Union. It’s expected to receive US approval in the first half of this year.
Simparica Trio is also expected to broaden Zoetis’ market share in the parasiticides sector, where it only ranks fourth.
Zoetis is also looking to explore the lucrative market of osteoarthritis treatments for cats and dogs.
Taking a page off the world’s top-selling drug, Abbott Laboratories’ (ABT) blockbuster rheumatoid arthritis treatment Humira, the animal health company plans to create pain medication based on the same technology. If Zoetis succeeds, then it’ll be the first company to address this unmet market.
Apart from these, Zoetis will also expand its services to include diagnostics as well as digital and data analytics.
In fact, the company has started investing in “precision livestock farming.” A good example of this initiative is its Smartbow technology, which is a dairy cow monitoring system that utilizes motion detectors. These are attached to the animals’ ears in an effort to identify patterns that can signify health issues.
Zoetis has been one of the most attractive stocks on the market since 2013.
While a lot of healthcare and biotechnology companies are at risk for increased volatility this year especially with the US presidential election, this animal health stock should be relatively resistant to political drawbacks.
https://www.madhedgefundtrader.com/wp-content/uploads/2020/03/zoetis.png468468Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-05-21 14:00:352020-05-21 15:40:40There is Still More Bang Per Buck with Zoetis
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png00Mad Hedge Fund Traderhttps://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.pngMad Hedge Fund Trader2020-05-21 13:06:052020-05-21 13:16:47May 21, 2020
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.